PI3K/AKT/mTOR hypersignaling in autoimmune lymphoproliferative disease engendered by the epistatic interplay of Sle1b and FASlpr

International Immunology

Volumn 19, Issue 4, 2007, Pages 509-522

  Xie, Chun ^a   Patel, Rahul ^a   Wu, Tianfu ^a   Zhu, Jiankun ^a   Henry, Tamika ^a   Bhaskarabhatla, Madhavi ^a   Samudrala, Renuka ^a   Tus, Katalin ^b   Gong, Yimei ^a   Zhou, Hui ^a   Wakeland, Edward K ^b   Zhou, Xin J ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CD150 ANTIGEN; EVEROLIMUS; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INITIATION FACTOR 4E BINDING PROTEIN 1; LYMPHOCYTE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; PROTEIN SLE1B; S6 KINASE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; B LYMPHOCYTE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; GENE LOCUS; GENETIC EPISTASIS; GENETIC MODEL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; EPISTASIS, GENETIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MULTIGENE FAMILY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; SPLEEN; SURVIVAL ANALYSIS;

EID: 34047170343     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxm017     Document Type: Article

References (48)

1. Chun, H. J. and Lenardo, M. J. 2001. Autoimmune lymphoproliferative syndrome: Types I, II and beyond. Adv. Exp. Med. Biol. 490:49.
2. Straus, S. E., Jaffe, E. S., Puck, J. M. et al. 2001. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98:194.
3. Rieux-Laucat, F., Le Deist, F., Hivroz, C. et al. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347.
4. Drappa, J., Vaishnaw, A. K., Sullivan, K. E., Chu, J. L. and Elkon, K. B. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1643.
5. Ohashi, P. S. 2002. T-cell signalling and autoimmunity: Molecular mechanisms of disease. Nat. Rev. Immunol. 2:427.
6. Scaffidi, C., Kirchhoff, S., Krammer, P. H. and Peter, M. E. 1999. Apoptosis signaling in lymphocytes. Curr. Opin. Immunol. 11:277.
7. Refaeli, Y., Van Parijs, L. and Abbas, A. K. 1999. Genetic models of abnormal apoptosis in lymphocytes. Immunol. Rev. 169:273.
8. Jackson, C. E., Fischer, R. E., Hsu, A. P. et al. 1999. Autoimmune lymphoproliferative syndrome with defective Fas: Genotype influences penetrance. Am. J. Hum. Genet. 64:1002.
9. Bleesing, J. J., Brown, M. R., Straus, S. E. et al. 2001. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 98:2466.
10. Shi, X., Xie, C., Kreska, D., Richardson, J. A. and Mohan, C. 2002. Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity. J. Exp. Med. 196:281.
11. Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B. and Pandolfi, P. P. 1999. Impaired Fas response and autoimmunity in Pten+/- mice. Science 285:2122.
12. Borlado, L. R., Redondo, C., Alvarez, B. et al. 2000. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J. 14:895.
13. Stambolic, V., Tsao, M. S., Macpherson, D., Suzuki, A., Chapman, W. B. and Mak, T. W. 2000. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60:3605.
14. Cantley, L. C. and Neel, B. G. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl Acad. Sci. USA 96:4240.
15. Dahia, P. L., Aguiar, R. C., Alberta, J. et al. 1999. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum. Mol. Genet. 8:185.
16. Li, J., Simpson, L., Takahashi, M. et al. 1998. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res. 58:5667.
17. Parsons, M. J., Jones, R. G., Tsao, M. S., Odermatt, B., Ohashi, P. S. and Woodgett, J. R. 2001. Expression of active protein kinase B in T cells perturbs both T and B cell homeostasis and promotes inflammation. J. Immunol. 167:42.
18. Suzuki, A., Yamaguchi, M. T., Ohteki, T. et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14:523.
19. Anzelon, A. N., Wu, H. and Rickert, R. C. 2003. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat. Immunol. 4:287.
20. Wendel, H. G., De Stanchina, E., Fridman, J. S. et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332.
21. Mills, G. B., Lu, Y. and Kohn, E. C. 2001. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl Acad. Sci. USA 98:10031.
22. Morel, L., Mohan, C., Yu, Y. et al. 1997. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J. Immunol. 158:6019.
23. Mohan, C., Alas, E., Morel, L., Yang, P. and Wakeland, E. K. 1998. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/ H2B/DNA subnucleosomes. J. Clin. Invest. 101:1362.
24. Morel, L., Blenman, K. R., Croker, B. P. and Wakeland, E. K. 2001. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc. Natl. Acad. Sci. USA 98:1787.
25. Wandstrat, A. E., Nguyen, C., Limaye, N. et al. 2004. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity. 21:769.
26. Cohen, P. L. and Eisenberg, R. A. 1991. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
27. Xie, C., Zhou, X. J., Liu, X. and Mohan, C. 2003. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum. 48:1080.
28. Gingras, A. C., Raught, B. and Sonenberg, N. 2001. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15:807.
29. Huang, S. and Houghton, P. J. 2003. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3:371.
30. Hosoi, H., Dilling, M. B., Shikata, T. et al. 1999. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 59:886.
31. Panwalkar, A., Verstovsek, S. and Giles, F. J. 2004. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100:657.
32. Majewski, M., Korecka, M., Kossev, P. et al. 2000. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl Acad. Sci. USA 97:4285.
33. Majewski, M., Korecka, M., Joergensen, J. et al. 2003. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75:1710.
34. Podsypanina, K., Lee, R. T., Politis, C. et al. 2001. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl Acad. Sci. USA 98:10320.
35. Boulay, A., Zumstein-Mecker, S., Stephan, C. et al. 2004. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64:252.
36. Croker, B. P., Gilkeson, G. and Morel, L. 2003. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun. 4:575.
37. Kumar, K. R., Li, L., Yan, M. et al. 2006. Regulation of B cell tolerance by the lupus susceptibility gene ly108. Science 312:1665.
38. Mannella, P. and Brinton, R. D. 2006. Estrogen receptor protein interaction with phosphatidylinositol 3-kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1/2 in the same population of cortical neurons: A unified mechanism of estrogen action. J Neurosci. 26:9439.
39. Guo, R. X., Wei, L. H., Tu, Z. et al. 2006. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem. Mol. Biol. 99:9.
40. Moe-Behrens, G. H., Klinger, F. G., Eskild, W., Grotmol, T., Haugen, T. B. and De Felici, M. 2003. Akt/PTEN signaling mediates estrogen-dependent proliferation of primordial germ cells in vitro. Mol. Endocrinol. 17:2630.
41. Kwon, C. H., Zhu, X., Zhang, J. and Baker, S. J. 2003. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl Acad. Sci. USA 100:12923.
42. Shi, Y., Gera, J., Hu, L. et al. 2002. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 62:5027.
43. Kotzin, B. L. 1997. Susceptibility loci for lupus: A guiding light from murine models? J. Clin. Invest. 99:557.
44. Tsao, B. P., Cantor, R. M., Kalunian, K. C. et al. 1997. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J. Clin. Invest. 99:725.
45. Wakeland, E. K., Liu, K., Graham, R. R. and Behrens, T. W. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397.
46. Kinlen, L. J. 1992. Malignancy in autoimmune diseases. J. Autoimmun. 5 Suppl A:363.
47. Sweeney, D. M., Manzi, S., Janosky, J. et al. 1995. Risk of malignancy in women with systemic lupus erythematosus. J. Rheumatol. 22:1478.
48. Mellemkjaer, L., Andersen, V., Linet, M. S., Gridley, G., Hoover, R. and Olsen, J. H. 1997. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 40:761